Trial 5GYN-23-2


A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic, Other
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Koji Matsuo, M.D.
Other Trial Staff:  Marissa Aldana, Coordinator, Margarita Carranza, D.M., America Casillas-Lopez, Coordinator, Apoorva Vishwanath, D.M., Leslie Guevara, Coordinator, Othesia Glasgow, D.M., Xochitl Quintero, Coordinator, Kimberly Arieli, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.